To accommodate the diverse variants generated by our sequencing chemistry and to address rare or difficult cases, we developed a comprehensive, integrated service known as the Molecular Tumor Board. This collaborative, interdisciplinary, board consists of expert scientists and physicians in genomics from across the western United States.

Every case is reviewed for therapy prioritization by expert oncologists and molecular pathologists for clinical quality. Personalized, interpretive treatment plans are then linked with verified, precision cancer medications.

The Molecular Tumor Board meets to discuss individual, effective treatment options for cases, based on genomic data and clinical relevance. These sessions are useful learning tools for clinicians to further scientific advancements in personalized medicine.

Molecular Tumor Board Members


Dr. Sheryl Krevsky Elkin, PhD

Sheryl Krevsky Elkin, PhD, is the Scientific Director at N-of-One, the leading provider of clinical interpretation for molecular diagnostic tests in oncology. For the past seven years, Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. As an early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions.
Haslem Derrick revised

Dr. Derrick Haslem, MD

Dr. Derrick Haslem, MD, is a Medical Oncologist and Director of Medical Oncology for Intermountain Healthcare. Dr. Haslem received his medical degree from the University of Utah School of Medicine and Residency and Fellowship training at the University of Utah Medical Center. Dr. Haslem has Board Certifications in Internal Medicine and Medical Oncology with expertise in targeted therapy and genomics.

Dr. Michael D. McPhee, FACS, MD

Michael D. McPhee, FACS, MD, is board-certified surgical oncologist with ProMedica Cancer Institute. He graduated from the SUNY Health Science Center, Syracuse, NY in 1990. Dr. McPhee lives and works in Sylvania, OH. He was recognized by US News & World Report as a Top Doctor in 2011 and 2012. Dr. McPhee has contributed to numerous publications, clinical trials and scholarly service. As a physician, Dr. McPhee is passionate about research and inspired by his patients’ willpower and drive to overcome cancer.

Dr. Lincoln Nadauld, MD PhD

Dr. Lincoln Nadauld, MD PhD, is the Director of Cancer Genomics at Intermountain Healthcare, an integrated healthcare system located in the Intermountain West. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he is part of the research faculty focusing on cancer genomics and personalized cancer medicine. Dr. Nadauld oversees the clinical implementation of genomic cancer medicine across Intermountain Healthcare’s 22 hospitals and 180 physician clinics.
Terence_Rhodes MD PhD revised

Dr. Terence Rhodes, MD, PhD

Dr. Terence Rhodes, MD, PhD, is an oncologist with expertise in immunotherapies at Intermountain Healthcare Southwest Cancer Center. Dr. Rhodes is certified by the American Board of Internal Medicine and is dedicated to research and cancer treatments using immunotherapies. A native of Millwood, West Virginia, Rhodes earned a bachelor’s degree from Marshall University in Huntington, West Virginia, and a medical degree from West Virginia University School of Medicine in Morganton. He completed graduate work at the National Cancer Institute and completed an internal medicine residency at West Virginia University Charleston Division in Charleston, followed by a hematology/oncology fellowship at Duke University in Durham, North Carolina.

Dr. Victor Villalobos, MD, PhD

Dr. Victor Villalobos, MD, PhD, is Assistant Professor for the Division of Medical Oncology University Colorado School of Medicine. Dr. Villalobos received his medical degree and PhD from Washington University School of Medicine. His training continued with Residency in Internal Medicine and a Fellowship in Medical Oncology at Stanford University. Dr. Villalobos specializes in the treatment and management of soft tissue and bone sarcomas. His clinical research focuses on the development of novel therapeutic regimens and modalities for treating different subtypes of sarcomas with new cytotoxic therapies, immunotherapy as well as other targeted therapies.